DBC2 is a tumor suppressor gene linked to breast and lung cancers. Although DBC2 belongs to the RHO GTPase family, it has a unique structure that contains a Broad-Complex/Tramtrack/Bric a Brac (BTB) domain at the C terminus instead of a typical CAAX motif. A limited number of functional studies on DBC2 have indicated its participation in diverse cellular activities, such as ubiquitination, cell-cycle control, cytoskeleton organization and protein transport. In this study, the role of DBC2 in protein transport was analyzed using vesicular stomatitis virus glycoprotein (VSVG) fused with green fluorescent protein. We discovered that DBC2 knockdown hinders the VSVG transport system in 293 cells. Previous studies have demonstrated that VSVG is transported via the microtubule motor complex. We demonstrate that DBC2 mobility depends also on an intact microtubule network. We conclude that DBC2 plays an essential role in microtubule-mediated VSVG transport from the endoplasmic reticulum to the Golgi apparatus.
Introduction
DBC2 is a tumor suppressor gene involved in the development of breast cancer. It is inactivated in more than half of breast cancer specimens and has been demonstrated to suppress growth of breast cancer cells. The deduced amino acid sequence revealed that DBC2 contains well-conserved RAS and broad-complex tramtrack bric a brac/poxvirus zinc finger (BTB/POZ) domains that classify DBC2 as a member of the RHOBTB family. The RAS domain of DBC2 has a high level of homology to that of small GTP-binding proteins (G-proteins), including the sites for binding to and hydrolysis of GTP. However, DBC2 is distinct from the typical RAS family member. DBC2 lacks the carboxyl terminal CAAX motif that is essential for isoprenylation, indicating a different role for DBC2 in association with the membrane. DBC2 has BTB domains in the middle of its structure, which makes DBC2 markedly bigger than most G-proteins. The unique structure of DBC2 suggests that it may be functionally divergent from canonical G proteins.
Although RHOBTB is an evolutionarily conserved protein with homologs in Mus musculus and Drosophila melanogaster, homologs are not found in all eukaryotes and are absent from Caenorhabditis elegans and Saccharomyces cerevisiae.
1 RHOBTB is found also in non-mammals, such as RacA of Dictyostelium discoideum. However, mammalian RHOBTB proteins and Dictyostelium RacA have considerable differences. 2 One of the more important distinctions involves the critical residues for GTPase activity that are conserved in RacA but not in human RHOBTB (for example, codons 86 and 88 of DBC2). We demonstrate here that DBC2 does not bind to GTP. Since proteins with GTPase activity are likely to play a different role from those without GTPase activity, mammalian RHOBTB may very well have a different evolutionary origin from that of Dictyostelium RacA. Indeed, the absence of Abbreviations used: BTB, broad-complex tramtrack bric a brac; POZ, poxvirus zinc finger; G-proteins, GTPbinding proteins; GEF, guanine nucleotide exchange factor; GAP, GTPase-activating protein; GDI, guanine nucleotide dissociation inhibitor; NSF, N-ethylmaleimidesensitive factor; FRAP, fluorescence recovery after photobleaching; FLIP, fluorescence loss in photobleaching; VSVG, vesicular stomatitis virus glycoprotein; ER, endoplasmic reticulum.
E-mail address of the corresponding author: hamaguchi@fordham.edu RHOBTB from C. elegans suggests that the mammalian RHOBTB emerged recently in evolutionary terms. As for DBC2, the orthologous genes are found only in mammals, implying that the function of DBC2 may be related to the high-level orchestration of cellular activity. This can be elucidated only by studying mammalian genes.
The RAS superfamily comprises five branches: the RAS, RHO, RAB, RAN and ARF families. Each branch contains GTPases that function as molecular switches in a wide variety of cellular pathways. 3 GTPases bounce between active and inactive states as one binds to GTP and the other to GDP, respectively. This GTP/GDP cycling is controlled by three types of regulatory proteins that frequently engage members of the RAS superfamily: guanine nucleotide exchange factors (GEFs); GTPase-activating proteins (GAPs); and guanine nucleotide dissociation inhibitors (GDIs). The RAS homologous (RHO) proteins are known to play a key role in actin organization, microtubule dynamics, membrane trafficking and transcriptional regulation. 4 As a reflection of their involvement in such diverse cellular pathways, RHO GTPases interact with a motley collection of GAPs and GEFs, and regulate similarly diverse downstream effectors. RND and RHOBTB are exceptional RHO proteins, in that they have mutations at the crucial residues for hydrolysis of GTP. In fact, RND does not hydrolyze GTP in vitro, which implies that essential GAPs remain undiscovered or GAPs are controlled by transcriptional regulation and/or protein degradation. 5, 6 The number of target effectors for the three best characterized GTPases (RHOA, RAC1 and CDC42) exceeds 60, but few effectors for the other members of RHO GTPases have been identified. RHOBTB proteins, including DBC2, have yet to be characterized, and their regulatory proteins and effectors are unknown.
The BTB/POZ domain is an evolutionarily conserved protein-protein interaction motif of approximately 115 amino acid residues. 7 Many BTB/POZ proteins are transcriptional regulators that mediate gene expression through the control of chromatin conformation. Such examples are BACH1, BACH2, PATZ and PLZF, all of which interact with other proteins through their BTB/POZ domains in a very specific manner. The interspecifically conserved residues within the BTB/POZ domain have been shown to be crucial for the interaction. Wellconserved, charged residues within the BTB/POZ domain are exposed into a pocket formed by the BTB/POZ domains of interacting proteins. Although the charged residues are not essential for oligomerization, they play a critical role in transcriptional regulation by the complex. 8 Other BTB/ POZ proteins with Kelch repeats have been reported to bind to actins. 9 BTB/POZ proteins have been demonstrated to recruit substrates for CUL3 ubiquitin ligases, suggesting the involvement of RHOBTBs in protein degradation pathways. 10 Their role as adapters requires specific recognition of the substrate that is bestowed by additional domains in some BTB/POZ proteins. DBC2 is shown to interact with CUL3 but its specific substrates have not been identified.
DBC2′s novel combination of structural domains, lack of a membrane anchor sequence at the C terminus and crucial mutation in the GTPase domain suggests that the function of DBC2 may not be deduced from other members of the RAS superfamily. Previous studies of RHOBTB have suggested several cellular functions. RHOBTB was found to suppress the overgrowth of Drosophila larval neuromuscular synapse induced by N-ethylmaleimide-sensitive factor (NSF). 11 Although the authors surmised that RHOBTB is a potential regulator of the cytoskeleton, it is possible that RHOBTB participates in other pathways that are relevant to the suppression of NSF neuromuscular junction overgrowth, including the ubiquitin pathway and signal transduction. In fact, DBC2 interacts with ubiquitin ligase like other BTB proteins, indicating its involvement in the ubiquitin pathway. 10 Expression microarray analysis revealed that DBC2 alters expression levels of genes in charge of cell-cycle control, apoptosis, cytoskeleton and membrane trafficking. 12 These findings infer that DBC2 participates in various cellular activities. As part of a comprehensive study on DBC2 function, its role in protein transport was investigated.
Fluorochromes allow real-time observation of protein movement in live cells and thorough analysis of subcellular localization of proteins. Additionally, manipulation of fluorescent signals facilitates the study of protein kinetics through techniques such as fluorescence recovery after photobleaching (FRAP) and fluorescence loss in photobleaching (FLIP). Vesicular stomatitis virus glycoprotein (VSVG)-EGFP (ts045), a well-characterized chimeric protein, has been utilized for a number of studies on protein transport. VSVG is transported from the endoplasmic reticulum (ER) to the Golgi apparatus by pre-Golgi structures along the microtubule tracks. 13 We demonstrate here that DBC2 knockdown severely incapacitates VSVG-EGFP (ts045) transport. Additionally, DBC2 transport depends on an intact microtubule network. These findings indicate that DBC2 plays a crucial role in VSVG transport in a microtubule-dependent manner.
Results

GTP binding assay of DBC2
A GTP binding assay was carried out to confirm that mutations of the critical residues in the RAS domain (codons 86 and 88) make DBC2 nonfunctional as a GTPase. A truncated mutant containing only codons 1 through 160 and wild-type DBC2 did not bind to GTP, whereas p21 RAS bound to GTP ( Figure 1 ). This result suggests that the RAS domain of DBC2, like that of RND, may play a distinctive role among RHO GTPases.
Endogenous DBC2 expression in 293 cells
The level of DBC2 expression varies depending on the type of cell. Certain cells are led to growth arrest by exogenous DBC2, while others tolerate DBC2. 1 In order to examine the expression level of endogenous DBC2 in 293 cells, DBC2 protein was stained with anti-DBC2 antibody N15 (Delta Labs). The expression of endogenous DBC2 was observed in the 293 cells ( Figure 2 ). Furthermore, the 293 cells continued to grow after transformation with DBC2 expression vector. The different responses to DBC2 may be explained by the cellular dependence on a particular biological pathway (see Discussion). We concluded that 293 cells are suitable for functional analysis of DBC2 due to their property of expressing endogenous DBC2 and ability to withstand exogenous DBC2 overexpression.
Kinetics of VSVG-EGFP (ts045) in 293 cells and SK-BR-3 cells
In order to verify the VSVG-EGFP (ts045) clone to be used in the experiments, its kinetics was examined in 293 and Sk-BR-3 cells. After transformation of 293 and SK-BR-3 cells, VSVG-EGFP (ts045) signal was observed mainly at the cellular membrane and Golgi apparatus during incubation at 37°C (Figure 3(a) ). VSVG-EGFP (ts045) is known to stay within the ER at a higher temperature, due to a reversible abnormal folding. 13 This was confirmed by observing that the transformants at a nonpermissive temperature (39°C) exhibited VSVG-EGFP (ts045) signal exclusively at the ER ( Figure  3(b) ). As the temperature was lowered to a permissive temperature (32°C), the VSVG-EGFP (ts045) signal began to accumulate at the Golgi apparatus (Figure 3(c) ). When a region of interest (ROI) was photobleached, the signal within the ROI recovered to more than 72% of the prebleached level within 60 s (σ = 10%). These observations are concordant with published data of VSVG-EGFP (ts045) kinetics in COS and U2OS cells.
14, 15 We can reasonably assume that 293 and SK-BR-3 cells transport VSVG-EGFP (ts045) in the same manner as well-characterized COS cells.
The role of DBC2 in VSVG transport
In order to determine the role of DBC2 in VSVG transport, DBC2 was knocked down in 293 cells and the kinetics of VSVG-EGFP (ts045) was studied (293-KD). Control 293 cells (293-C) were prepared as described in Materials and Methods, and analyzed alongside 293-KD cells. There was no noticeable difference in VSVG-EGFP (ts045) kinetics between 293-C and wild-type 293 cells. The distribution of the fluorescent signal was observed at the cellular membrane and the Golgi apparatus. The recovery curve and the mobile fraction of VSVG-EGFP (ts045) in the 293-C cells were indistinguishable from those in the wild-type 293 cells. In contrast, the recovery curve of VSVG-EGFP (ts045) in the 293-KD cells was markedly different from that in the 293-C cells. The mobile fraction was diminished significantly to 22% (σ = 6.45%) (p < 0.01) (Figure 4 ). In addition, VSVG-EGFP (ts045) in 293-KD cells was distributed in a distinct manner ( Figure 5 ). The signal did not accumulate at the Golgi apparatus but an intense signal was observed near the ER. Although a signal was observed at the cellular membrane, it was raggedly dispersed instead of neatly defined. VSVG-EGFP (ts045) modification at the Golgi apparatus was probably disrupted, which inhibited normal alignment of VSVG-EGFP (ts045) at the final destination. Two possible mechanisms are considered: (1) DBC2 facilitates the connection between VSVG and the microtubule cellular motor system. In this scenario, DBC2 knockdown would incapacitate efficient VSVG transport to the Golgi and subsequently lead to congregation of VSVG without posttranslational modification at the cellular membrane. (2) DBC2 is part of the tethering complex that connects VSVG to the pre-Golgi structure. Without DBC2, VSVG is not transported to or accumulated at the Golgi apparatus. The export of VSVG from the ER is not affected by DBC2 knockdown, enabling VSVG to move freely by diffusion. The absence of signal accumulation at the Golgi apparatus may be explained by the second hypothesis. 
Kinetics of GFP-DBC2 in 293 cells and SK-BR-3 cells
The GFP-DBC2 signal in 293 and SK-BR-3 cells was distributed homogenously throughout the cytoplasm when it was abundantly expressed. FRAP analysis revealed a quick recovery of the GFP-DBC2 signal (88% in 20 s, σ = 5.4%) in 293 cells (Figure 4 ). Since RHO proteins bind to actin and participate in regulation of cytoskeletal dynamics, we investigated DBC2 kinetics after depolymerizing microtubules with 1 μM nocodazole. Although DBC2 distribution seemed unchanged, its movement, measured by FRAP analysis, was restricted (p < 0.01). After photobleaching the ROI, the fluorescent signal began to recover and reached a plateau in 20 s with 40% signal recovery (σ = 2.7%) (Figure 4) . We speculate that the initial recovery phase represents free movement of DBC2 near the ROI. The lower recovery ratio and earlier saturation are caused by the inhibition of distant traveling, which indicates that an intact microtubule network is essential for long-range transport of DBC2. These findings imply that free diffusion of DBC2 is restricted by binding to other proteins or saturation of DBC2 in the area. Indeed, immunocytochemical analysis demonstrated the localization of DBC2 alongside the microtubules (Figure 6 ). DBC2 was distributed widely in the cytoplasm and, unlike VSVG, did not appear to migrate heavily near particular organelles. This supports the hypothesis that DBC2 is a structural component of the tethering complex to the cellular motor system. Further experiments are needed to test this hypothesis.
Discussion
We demonstrated that DBC2 plays a vital role in VSVG transport and depends upon an intact microtubule network to remain mobile. Previous work established that the microtubule network is essential for VSVG transport. 16 However, there is still the crucial question of how DBC2 participates in VSVG transport. There are several possible modes of action. (1) DBC2 is necessary for the export of VSVG from the ER. (2) DBC2 catalyzes the connection of VSVG to the cellular motor system. (3) DBC2 is a component of the structure that connects a VSVG intermediate complex to the cellular motor system. VSVG-EGFP (ts045) is not confined in the ER even when DBC2 is knocked down, indicating that DBC2 is dispensable for export from the ER. Since GFP-DBC2 traveled in a microtubule dependent manner without losing the fluorescent signal, at least a certain portion of DBC2 is likely to bind to the cellular motors directly or indirectly. This finding corroborates previously published data that VSVG transport does not rely on vesicles. 13 In addition, DBC2 is actively transported even in the absence of VSVG-EGFP (ts045). These findings support the third mode of action (though the second mechanism remains possible) and prompt several questions. Which proteins rely on DBC2 for connection to the cellular motor? Is the role of DBC2 limited to non-vesicular transportation? Does DBC2 bind to the cellular motor directly? If not, what other proteins compose the tethering system? These questions need to be addressed in future research.
Endogenous DBC2 was observed in the nucleus as well as in the cytoplasm in some cells. The molecular mass of DBC2 is 83 kDa, exceeding the size limitation for free permeability (up to 9 nm, e.g. 40-60 kDa) into the nucleus. DBC2 has biological signatures that appear in nuclear proteins in the PROCITE database. 17 Interestingly, DBC2 does not have a known nuclear localization signal (NLS), which was confirmed by PredictNLS, an application that predicts NLS. 18 This discrepancy is not uncommon, since only 43% of the known nuclear proteins have matching NLS detectable by PredictNLS. These findings indicate that DBC2 may be transported into the nucleus by an unknown nuclear transport system that recognizes uncharacterized motifs. Some nuclear G-proteins are transported between the nucleus and the cytoplasm. It is conceivable that DBC2 might shuttle in the same way.
SK-BR-3 and 293 cells are resistant to DBC2 expression despite the role of DBC2 as a tumor suppressor that works adversely in certain cells. Different responses to DBC2 may be caused by the nature of DBC2-sensitive cells that have become dependent on cellular pathways negatively regulated by DBC2. Many cellular pathways are redundant, and the obstruction of signal transduction at a certain point is usually tolerated. However, some cancer cells have developed dependence on a particular cellular pathway, most commonly the oncogenic pathway. For example, BCR-ABL function has become vital in a subset of leukemia cells with a Philadelphia chromosome. Imatinib, a BCR-ABL inhibitor, works adversely in these cells, but does not damage other cells severely, since they have alternatives to the ABL pathway. 19 Future experiments to test this hypothesis will include determining DBC2 sensitivity for a number of tumor cells and investigating the cellular pathways that involve DBC2 in these cells. 
Materials and Methods
Reagents
All enzymes were obtained from New England Bio Labs (Beverly, MA) unless stated otherwise. Thermo-stable DNA polymerases were purchased from Applied Biosystems (Foster City, CA). Oligonucleotides were synthesized by Sigma Genosys (The Woodlands, TX). Rabbit anti-DBC2 polyclonal antibody (N15) was obtained from Delta Biolabs (Campbell, CA). Mouse monoclonal anti-rabbit IgG conjugated with TRITC was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). HRP-conjugated anti-β actin antibody and anti-γ tubulin antibody were purchased from Sigma (St. Louis, MO). Alexa Fluor 568-conjugated goat anti-mouse IgG was purchased from Invitrogen (Carlsbad, CA). Guanosine 5′-[α- 
Constructs
Full-length cDNA of DBC2 was obtained from normal breast cDNA library, Soares 3NbHBst (the I.M.A.G.E. Consortium) and cloned into BamHI-EcoRI sites of pCMVtag2B plasmid (Stratagene, La Jolla, CA) to create pCMVtag2B-DBC2. The entire insert was sequenced for both directions to verify the absence of mutations. The DBC2 open reading frame (ORF) was inserted into the pEGFP-C1 vector to create GFP-DBC2 fusion protein (pEGFP-DBC2). The same ORF was cloned into pRSET-A vector to generate pRSET-DBC2. A truncated DBC2 ORF (nucleotides 1-480) was inserted into the pRSET-A vector so that the expressed protein would contain only a RAS domain (pRSET-DBC2-ΔBTB). The VSVG-EGFP (ts045) construct was donated by Dr Lippincott-Schwartz at NIH. 13 The constructs were transfected with Oligofectamine (Invitrogen, Carlsbad, CA) or FuGene6 (Roche, Indianapolis, IN), following the manufacturer's instructions.
GTP binding assay
Wild-type and mutant DBC2 proteins were produced from pRSET-DBC2 and pRSET-DBC2-ΔBTB in Escherichia coli strain BL21 and subsequently purified with NiCAM HC resin (Sigma-Aldrich, St. Louis, MO). RAS protein was a gift from Dr Linda Van Aelst. DBC2-ΔBTB (22 kDa), wt DBC2 (83 kDa), RAS (positive control) and albumin (negative control) were analyzed by SDS-PAGE (12% (w/v) polyacrylamide gel). The proteins were transferred to a nitrocellulose membrane and submerged in a buffer (10 mM NaHCO 3 , 3 mM Na 2 CO 3 , pH 9.8) for 15 min. The membrane was rinsed with a GTP-binding buffer (50 mM Lamin siRNA (Dharmacon Inc.) was used as a control. 12 Target cells were transformed with 200 nM siRNA using Oligofectamine Reagent (Invitrogen, Carlsbad, CA), following the manufacturer's instructions. The cells were observed 24 h after transformation. The 293 cells with DBC2 knockdown (293-KD) and control 293 cells (293-C) were prepared side by side from the same progenitor cells to minimize biological artifacts. Both cells were treated with transformation reagents in the same manner, except for the addition/subtraction of siRNAs: 293-KD with siRNAs for DBC2 and 293-C without siRNA. The effectiveness of siRNA was verified by immunocytochemistry.
Microscopy
All imaging of live cells was performed using a Zeiss LSM 510 confocal microscope system (Carl Zeiss). Cells were plated on an acid-treated coverslip (0.17 mm thick) and then transformed with the constructs of choice 24 h before microscopic observation. The slide with cells was set in a Focht Chamber System 2 (FCS2) that was maintained at 37°C. Confocal fluorescence images were acquired with a Zeiss Plan Apochromat (oil, 63×, 1.4 NA) objective and an argon/krypton laser. For quantitative analysis, the pinhole was opened to collect fluorescence from the entire depth of the cell. The EGFP constructs were imaged with a filter set 44 (excitation: BP 475/40, beam splitter: FT500, emission: BP 530/50). Confocal fluorescence images were acquired with a confocal laser scanning microscope (CLSM, Zeiss Axiovert 100). Collected images were analyzed with Carl Zeiss LSM software and converted to QuickTime movies. Singleframe images were exported as TIFF files and processed with Photoshop CS for presentation. Measurements of fluorescence intensity within the ROI and whole cell were acquired by LSM software and exported to Microsoft Excel spread-sheets for further calculation. For FRAP, five images were taken before photobleaching at low laser intensity (<1%). The ROI was then scanned six to ten times with the laser line at full laser power at zero attenuation. Immediately after photobleaching the cell, the fluorescence recovery within the ROI was monitored by time-lapse imaging (4.98 s/frame) at low laser intensity (<1%) unless stated otherwise. All experiments were repeated for at least three independent transformations. Each transformation was accompanied by controls with an empty vector transfection and unrelated construct. 
